FDA accepts Bristol-Myers Squibb’s application for Opdivo (nivolumab) plus Yervoy
Bristol-Myers Squibb announced the FDA has accepted its sBLA for priority review of Opdivo (nivolumab) plus Yervoy (ipilimumab) to treat intermediate- and poor-risk patients with advanced renal cell carcinoma). The FDA also previously granted Breakthrough Therapy Designation for this application. December 13, 2017